Table 1

Baseline demographic, clinical, biochemical, functional, quality of life and imaging characteristics. All values are median (first quartile to third quartile) unless otherwise stated

CharacteristicPatients (n=93)
Age mean (95% CI)56.6 (53.9 to 59.4)
Female n (%)63/93 (67.7)
Duration of RA (years)7.0 (4.5–9.5)
Duration of remission (months)22 (12–34)
DMARD therapy
No treatment9
Methotrexate only37
Sulphasalazine only22
Leflunomide only4
Hydroxychloroquine only2
Gold only2
Combination dual therapy12
Combination triple therapy5
RF positive n (%)39/93 (41.9)
Anti-CCP positive n (%)38/64 (59.4)
Shared epitope positive n (%)55/91 (60.4)
XR erosion present n (%)70/85 (82.4)
HAQ-DI score mean (95% CI)0.337 (0.277 to 0.397)
RAQoL mean (95% CI)6.4 (5.3 to 7.6)
TJC28>1 n (%)25/93 (26.9)
SJC28>1 n (%)39/93 (41.9)
CRP>0 n (%)51/93 (54.8)
TJC280 (0–2)
SJC281 (0–4)
CRP5 (0–8)
DAS282.29 (1.79–3.19)
SDAI6.1 (3.0–9.1)
SDAI remission n (%)31/93 (33.3)
DAS28 remission n (%)52/93 (55.9)
1981 ACR remission n (%)50/93 (53.8)
2011 ACR/ EULAR remission n (%)13/93 (14.0)
Number of patients with US GS synovial hypertrophy83/93 (89.2%)
Number of joints with US GS synovial hypertrophy per patient (/8)3 (2–5)
Number of patients with PD activity58/93 (62.4%)
Number of joints with PD activity per patient (/8)1 (0–2)
Number of patients with US erosions present65/93 (69.9%)
  • ACR, American College of Rheumatology; Anti-CCP, anticitrullinated protein antibody; CRP, C reactive protein; DAS28, 28-joint count Disease Activity Score; DMARD, disease-modifying antirheumatic drugs; EULAR, European League Against Rheumatism; HAQ-DI, Health Assessment Questionnaire Disability Index; PD, ultrasound power Doppler; RA, rheumatoid arthritis; RAQoL, RA Quality of Life Questionnaire score; RF, rheumatoid factor; SDAI, Simplified Disease Activity Index; SJC28, swollen 28-joint count; TJC28, tender 28-joint count; US, ultrasound; US GS, ultrasound Grey Scale; XR, x-ray.